Nobel prize winner Craig Mello joined the board of directors at Grove Instruments Inc., where he hopes to help make the first non-invasive blood glucose meter a reality.
Mello said he wanted to take a more active role in the Worcester, Mass.-based firm after two years as an advisor.
“Experiencing the 24-hour-a-day every day nature of this disease really makes you appreciate the tremendous potential benefit of Grove’s technology,” Mello, who has a child with the condition, said in prepared remarks. “I wanted more involvement – an opportunity to make a bigger impact on the success of the company and its technology.”
Mello, the Blais University Chair of Molecular Medicine and co-director of the RNA Therapeutics Institute at the U-Mass. medicine school, won the 2006 Nobel Prize for medicine along with Andrew Fire for their research on RNA interference.
RNAi describes how living cells regulate gene activity. Since Mello and Fire delineated its mechanisms in 1998, via their close scrutiny of the C. elegans worm, it’s become an important tool for genetic researchers.
Grove Instruments is developing a blood glucometer designed to obviate the need for “finger-prick” blood testing for Type I diabetics. The technology uses an “optical bridge” to scan tissue and filter background tissue from the resulting image. The device can then detect the glucose levels in blood vessels, according to the company’s website.
GE Healthcare taps Hausmann to head MRI segment
GE Healthcare tapped Richard Hausmann as the new general manager of the company’s magnetic resonance business, effective Jan. 1, 2012. Read more